使

Olivia Monton1, Andrei Gurau2, Kimberly Kopecky3

  • 1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

PubMed
概括

在2004年至2020年期间,晚期逆皮质肉瘤 (RPS) 的息疗法使用率从2.6%增加到6.5%. 年龄,保险状况和疾病阶段等因素影响了其利用率,但整体率仍然很低.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K